AU2004222409B2 - Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy - Google Patents

Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy Download PDF

Info

Publication number
AU2004222409B2
AU2004222409B2 AU2004222409A AU2004222409A AU2004222409B2 AU 2004222409 B2 AU2004222409 B2 AU 2004222409B2 AU 2004222409 A AU2004222409 A AU 2004222409A AU 2004222409 A AU2004222409 A AU 2004222409A AU 2004222409 B2 AU2004222409 B2 AU 2004222409B2
Authority
AU
Australia
Prior art keywords
pab
aze
cholesterol
prodrug
melagatran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004222409A
Other languages
English (en)
Other versions
AU2004222409A1 (en
Inventor
Margaretha Grind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2004222409A1 publication Critical patent/AU2004222409A1/en
Application granted granted Critical
Publication of AU2004222409B2 publication Critical patent/AU2004222409B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pyrrole Compounds (AREA)
AU2004222409A 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy Ceased AU2004222409B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0306615.6A GB0306615D0 (en) 2003-03-22 2003-03-22 New use
GB0306615.6 2003-03-22
PCT/SE2004/000417 WO2004082702A1 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Publications (2)

Publication Number Publication Date
AU2004222409A1 AU2004222409A1 (en) 2004-09-30
AU2004222409B2 true AU2004222409B2 (en) 2007-03-08

Family

ID=9955311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004222409A Ceased AU2004222409B2 (en) 2003-03-22 2004-03-19 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Country Status (17)

Country Link
US (1) US20060183692A1 (https=)
EP (1) EP1608311B1 (https=)
JP (1) JP2006520813A (https=)
KR (1) KR20050114237A (https=)
CN (1) CN1761479A (https=)
AT (1) ATE475417T1 (https=)
AU (1) AU2004222409B2 (https=)
BR (1) BRPI0408522A (https=)
CA (1) CA2517191A1 (https=)
DE (1) DE602004028348D1 (https=)
ES (1) ES2346969T3 (https=)
GB (1) GB0306615D0 (https=)
MX (1) MXPA05010159A (https=)
NO (1) NO20054285L (https=)
NZ (1) NZ542505A (https=)
WO (1) WO2004082702A1 (https=)
ZA (1) ZA200507614B (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432537A2 (en) * 1989-11-24 1991-06-19 Iketon Farmaceutici S.R.L. Supersulfated heparins
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432537A2 (en) * 1989-11-24 1991-06-19 Iketon Farmaceutici S.R.L. Supersulfated heparins
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Also Published As

Publication number Publication date
AU2004222409A1 (en) 2004-09-30
CA2517191A1 (en) 2004-09-30
MXPA05010159A (es) 2005-11-16
HK1084329A1 (en) 2006-07-28
EP1608311A1 (en) 2005-12-28
JP2006520813A (ja) 2006-09-14
ZA200507614B (en) 2006-06-28
GB0306615D0 (en) 2003-04-30
NO20054285L (no) 2005-10-20
CN1761479A (zh) 2006-04-19
NO20054285D0 (no) 2005-09-16
KR20050114237A (ko) 2005-12-05
BRPI0408522A (pt) 2006-03-07
EP1608311B1 (en) 2010-07-28
DE602004028348D1 (de) 2010-09-09
US20060183692A1 (en) 2006-08-17
ES2346969T3 (es) 2010-10-22
NZ542505A (en) 2009-01-31
ATE475417T1 (de) 2010-08-15
WO2004082702A8 (en) 2005-03-24
WO2004082702A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
US10449154B2 (en) Treatment of NASH with Gemcabene
RU2294744C2 (ru) Применение розувастатина (zd-4522) в лечении гетерозиготной семейной гиперхолестеринемии
EP1660066B1 (en) Pharmaceutical composition comprising a combination of metformin and a statin
US20140121229A1 (en) Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an hmg coa reductase inhibitor
JP2012232995A (ja) 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
JPH04225916A (ja) 脂血障害の治療用組成物
JP2011137023A (ja) コレステロール低下薬の使用
AU2004222409B2 (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
NZ501844A (en) Alkanoyl L-carnitine in combination with a statin (simvastatin, lovastatin, provastatin or fluvastatin) for treating abnormal lipid metabolism disorders
EP3170495B1 (en) Gemcabene for treating pancreatitis
HK1084329B (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
RU2007149337A (ru) Новый способ лечения гиперлипидемии
RU2246302C2 (ru) Фармацевтическая композиция для профилактики и лечения нарушений липидного обмена
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
JP2002145774A (ja) 医薬組成物
HK1238159A1 (en) Gemcaben for treating pancreatitis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired